Advanced Nootropic

Why These Combine

A cholinergic design for experienced users: noopept drives acetylcholine demand while citicoline and ALCAR supply it, phosphatidylserine protects neuronal membranes, and Lion's Mane adds slow neuroplasticity. Noopept is the experimental centre — start low, cycle, and pair with choline. Here is what the evidence for each piece actually is. Noopept's neurotrophic mechanism — more BDNF and NGF expression — was demonstrated in rat hippocampus after single and 28-day dosing (Ostrovskaya 2008); its clinical record is a Russian comparison against piracetam in patients with mild cognitive disorders of vascular or traumatic origin (Neznamov 2009). There is no controlled trial of noopept in healthy adults, and no approved labelling anywhere in the US or EU, which means no regulated manufacturing standard behind the powder you would buy. Citicoline is the best-evidenced compound in the stack: 250–500 mg a day for 28 days improved attention and psychomotor speed in 75 healthy adolescent males (McGlade 2019), and 500 mg for 12 weeks improved episodic memory in 100 adults aged 50–85 with age-associated memory impairment (Nakazaki 2021). ALCAR's meta-analysis benefit — effect size 0.20 — comes from trials in mild cognitive impairment and early Alzheimer's at 1.5–3 g a day (Montgomery 2003), three to six times the 500 mg here; and the strongest randomised evidence about ALCAR is a trial showing harm, in women on taxane chemotherapy (Hershman 2018). Phosphatidylserine at 100 mg sits at the bottom of the 100–300 mg range that improved delayed recall only in older adults with low baseline scores (Kato-Kataoka 2010). Lion's Mane at 1 g is a third of the 3 g a day used in the single controlled trial, in 30 adults with mild cognitive impairment (Mori 2009). Compared with the Memory & Recall stack this swaps bacopa — which has a meta-analysis in its favour — for noopept, which does not, and adds ALCAR; compared with Executive Performance it drops the cortisol and magnesium components. Verdict: the four supplement-grade components are available in better-evidenced combinations elsewhere on this site; the only reason to choose this stack is noopept, and the only honest statement about noopept is that its benefit in healthy adults is undemonstrated and its regulatory status rules out any quality assurance.

• New to stacks? Build your first one step by step — this is not a starting point→
• Recommended entry point: the Beginner Starter stack→
• Same memory goal without the unapproved compound — the Memory & Recall stack→

References

1. 1.Neznamov & Teleshova 2009, Neurosci Behav Physiol — Noopept's main human trial was in a clinical (not healthy) population, comparable to piracetam.
2. 2.Ostrovskaya 2008, Bull Exp Biol Med — Rat study: Noopept (GVS-111) increased NGF and BDNF mRNA expression in the hippocampus after acute administration, with the effect potentiated rather than lost after 28 days of dosing; cortical expression fell after a single dose. (animal study — the source of the BDNF/NGF mechanism claim)
3. 3.McGlade 2019, J Atten Disord — 75 healthy adolescent males randomised to 250 or 500 mg citicoline or placebo for 28 days: improved attention (p=0.02) and psychomotor speed (p=0.03) versus placebo.
4. 4.Montgomery 2003, Int Clin Psychopharmacol — Meta-analysis of double-blind placebo-controlled trials of 3–12 months at 1.5–3.0 g/day in mild cognitive impairment and early Alzheimer's disease: integrated summary effect size 0.201 (95% CI 0.107–0.295); benefit visible by 3 months; well tolerated. (clinical populations at three to six times the dose used here)
5. 5.Kato-Kataoka 2010, J Clin Biochem Nutr — 78 adults aged 50–69 with memory complaints: soy phosphatidylserine 100 or 300 mg/day for 6 months improved delayed verbal recall only in the subgroup with low baseline scores; the whole-group comparison with placebo was null.
6. 6.Nakazaki 2021, J Nutr — Citicoline improved memory in healthy older adults.
7. 7.Hershman 2018, J Natl Cancer Inst — SWOG S0715, 409 women on adjuvant taxane chemotherapy: ALCAR 1000 mg three times daily made peripheral neuropathy significantly WORSE than placebo (−1.39 points, 95% CI −2.48 to −0.30, P = .01), still measurable two years on. Listed here because ALCAR is in this stack and the trial is the strongest evidence that exists about it. (randomised trial showing harm, in a specific population)
8. 8.Mori 2009, Phytother Res — Double-blind trial in 30 adults aged 50–80 with mild cognitive impairment: 3 g/day Hericium erinaceus improved cognitive scores over 16 weeks, and the gain was significantly lost 4 weeks after stopping. (small, and in an impaired population rather than healthy adults)